News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Athenex, A US-China Cancer Company, Stages $66 Million U.S. IPO



6/16/2017 9:23:54 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Athenex, a US-China cancer biopharma, completed a $66 million IPO on the NASDAQ exchange. Although that was the low end of the expected range, the company's shares have climbed 24% since they began trading. Athenex is developing a two-drug combination that would allow oral administration of common IV chemotherapies. The company is based in Buffalo, New York. It has partnered with New York State officials to build facilities there and with Chongqing to build a China manufacturing plant. It also has an R&D lab in Hong Kong.

Read at ChinaBio Today


comments powered by Disqus
Athenex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES